Cited by CrossRef (7)
- Eun Jeong Won, Hui-Ju Kim, Yu Jeong Lee, Moon-Ju Kim, Hae-In Lee, Hyun Hee Jang, Seong Hoon Kim, Ji-Hyoun Kang, Ki-Jeong Park, Seung Cheol Shim, Sungsin Jo, Tae-Hwan Kim, Tae-Jong Kim. CCL20 inhibition for treating inflammation in ankylosing spondylitis. 2023;62:4000
- Seoung Wan Nam, Jihye Lim, Dae Jin Park, Jun Young Lee, Jae Hyun Jung, Dae Ryong Kang. Epidemiologic Trends and Socioeconomic Disparities of Ankylosing Spondylitis in South Korea: A Nationwide Population-Based Study, 2010–2021. Yonsei Med J 2024;65
- Hong Ki Min, Hae-Rim Kim, Sang-Heon Lee, Bora Nam, Ji Hui Shin, Tae-Hwan Kim. Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review. International Immunopharmacology 2024;134:112167
- Ye Zhang, Wei Liu, Junda Lai, Huiqiong Zeng. Genetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers. Front. Immunol. 2024;15
- Dong-Hyuk Moon, Aran Kim, Byung-Wook Song, Yun-Kyung Kim, Geun-Tae Kim, Eun-Young Ahn, Min-Wook So, Seung-Geun Lee. High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis. Pharmaceuticals 2023;16:379
- Subin Hwang, Ye‐Jee Kim, Soo Min Ahn, Bon San Koo. Incidence rate of chronic kidney disease and its association with long‐term nonsteroidal anti‐inflammatory drug use in ankylosing spondylitis: A nationwide population‐based study. Int J of Rheum Dis 2024;27
- Chanhyeok Jeon, Yurin Jang, Seung Hoon Lee, Subin Weon, Hyosun Park, Suein Lee, Younseo Oh, Sung Hoon Choi, Sung Eun Wang, Tae-Hwan Kim, Il-Hoon Sung, Sungsin Jo. Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis. International Immunopharmacology 2023;118:110132
